/ELVN

Enliven Therapeutics Inc

ELVN

$54.32USD↓-3.40%-1.91 today

MARKET CAP

4.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$54 – $57

52W RANGE

$15

$62

AI Summary

Stalk

TrimMedium

ELVN is in a Stage 4 decline confirmed by a decisive support failure below the 9/20 EMAs, reinforcing a medium-term bearish bias. Price is extended and oversold, so timing is neutral—defer execution and look to sell into resistance around the broken $56.20–$57.50 zone on any bounce.

↑Stifel maintains Buy rating with $82 price target
↑Cash position of $895.2M funds R&D runway through 2030
↓Q2 2026 net loss of $32.5M ($0.49/share) highlights profitability strain

Full analysis →

Buying

9

institutions

Selling

4

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	4.36 M	221.25 M	+675.00 K	+53.2%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	2.14 M	108.66 M	+269.48 K	+48.1%	0.01%
BA Balyasny Asset Management L.P. Q2 2026	BUY	607.19 K	30.81 M	+297.16 K	+153.6%	0.04%
MM Millennium Management LLC Q2 2026	BUY	411.36 K	20.88 M	+66.04 K	+54.2%	0.01%
AC Adar1 Capital Management, LLC Q2 2026	BUY	387.72 K	19.68 M	+58.18 K	+52.3%	0.91%
WP Woodline Partners LP Q2 2026	SELL	347.14 K	17.62 M	+-256.20 K	-25.5%	0.05%
TR T. Rowe Price Investment Management, Inc. Q2 2026	BUYNEW	300.89 K	15.27 M	+300.89 K	+0.0%	0.01%
EP Eversept Partners, LP Q2 2026	BUYNEW	136.63 K	6.93 M	+136.63 K	+0.0%	0.36%
JC Jpmorgan Chase & Co Q2 2026	BUY	37.89 K	2.06 M	+17.07 K	+170.4%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUY	32.72 K	1.66 M	+10.49 K	+90.5%	0.01%
JH Janus Henderson Group Plc Q1 2026	SELL	22.00 K	862.40 K	+-1.65 M	-96.7%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	0.00	0.00	+-39.60 K	-100.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	0.00	0.00	+-25.00	-100.0%	0.00%